Coupled plasma filtration adsorption.
BACKGROUND
Severe sepsis and septic shock are perhaps the major cause of morbidity and mortality in Intensive Care. Their pathogenesis is only partly understood. Circulating peptides and lipid-derived substances (so-called mediators), however, appear to participate in the development of organ dysfunction. It might be possible to treat plasma in such a way that the injurious effect of mediators can be attenuated.


METHODS
Several ex vivo studies have shown that it is technically possible to adsorb mediators by means of specially developed sorbents. The application of these sorbents to the treatment of plasma in animals with experimental sepsis has shown that several markers of inflammation can be attenuated and that animal survival can be increased. We have recently transferred such technology to the treatment of human septic shock using a technique called Coupled Plasma Filtration Adsorption (CPFA). CPFA was found to attenuate the hypotension of septic shock and to dramatically alter the immuno-paralytic toxicity of septic plasma. Monocytes of patients treated with CPFA underwent a major improvement in their ability to respond to endotoxin.


CONCLUSIONS
CPFA represents a promising new approach to blood purification in sepsis. The findings associated with its application to humans highlight the importance of continuing to investigate blood purification as a possible approach to the treatment of septic shock, the potential usefulness of the humoral theory of sepsis, and the dominant state of immunosuppression associated with established septic shock.
Bellomo
Rinaldo
R
Department of Intensive Care, Austin & Repatriation Medical Centre, Studley Rd, 3084, Heidelberg, Victoria, Melbourne, Australia. rinaldo.bellomo@armc.org.au
Tetta
Ciro
C
Ronco
Claudio
C
D000327:Adsorption; D016207:Cytokines / Q000378:metabolism; D005374:Filtration; D006706:Homeostasis; D006801:Humans; D066298:In Vitro Techniques; D018836:Inflammation Mediators / Q000302:isolation & purification; D009000:Monocytes; D010949:Plasma; D010951:Plasma Exchange; D010956:Plasmapheresis / Q000379:methods; D017582:Renal Replacement Therapy; D018805:Sepsis / Q000097:blood* / Q000628:therapy*
D016207:Cytokines; D018836:Inflammation Mediators